口服乙醇治疗酒精戒断综合征:英国国家卫生服务体系实施后的初步发现与未来方向
该研究回顾性比较了两家急性照护机构中接受口服乙醇或苯二氮䓬类药物治疗的酒精戒断患者,乙醇组93例(84%男性,平均年龄46.5岁),苯二氮䓬组50例(82%男性,平均年龄50.9岁),采用逆倾向评分加权部分校正两组人群差异。乙醇组住院可能性显著降低(OR 0.206,95%CI 0.066-0.641,Wald卡方P=0.006);在未入院者中,治疗类型对住院时长或需要用药的次数无显著影响;在入院者中,治疗对住院时长无显著影响。作者认为口服乙醇作为综合照护计划的一部分可能减少非计划入院,但初步发现需前瞻性研究进一步评估。
要点
- 乙醇组住院可能性显著低于苯二氮䓬组:OR 0.206(95%CI 0.066-0.641),Wald卡方P=0.006。
- 未入院患者中,乙醇与苯二氮䓬对住院时长及需要用药的次数无显著影响。
- 入院患者中,治疗类型对住院时长无显著影响。
- 乙醇处方纳入标准:谵妄震颤高风险,或有害饮酒史(通常≥30单位/天,1单位=8克酒精;1标准美国饮品=14克酒精),或已知严重酒精戒断、酒精相关癫痫或谵妄震颤史。
- 作者认为在严重酒精戒断高风险个体中,乙醇作为综合照护计划的一部分可能减少非计划入院,但初步发现需前瞻性研究进一步评估。
适用人群与场景
- 在英国急性国家卫生服务体系内就诊的酒精戒断患者,接受口服乙醇或苯二氮䓬类药物治疗。
- 乙醇处方纳入标准:谵妄震颤高风险,或有害饮酒史(通常≥30单位/天;1单位=8克酒精;1标准美国饮品=14克酒精),或已知严重酒精戒断、酒精相关癫痫或谵妄震颤史。
诊断标准与关键阈值
- 乙醇处方纳入标准:谵妄震颤高风险,或有害饮酒史(通常≥30单位/天;1单位=8克酒精;1标准美国饮品=14克酒精),或已知严重酒精戒断、酒精相关癫痫或谵妄震颤史。
研究设计与关键结果
- 回顾性研究,数据来自两家急性照护机构,纳入接受苯二氮䓬类(50例,82%男性,平均年龄50.9岁)或乙醇(93例,84%男性,平均年龄46.5岁)治疗的酒精戒断患者,采用逆倾向评分加权部分校正两组人群差异。
- 乙醇组住院可能性显著降低:OR 0.206(95%CI 0.066-0.641),Wald卡方P=0.006。
- 未入院患者中,治疗类型对住院时长或需要用药的次数无显著影响。
- 入院患者中,治疗类型对住院时长无显著影响。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文自述数据集存在局限性,但未具体说明;作者指出初步发现需前瞻性研究进一步评估。
对床旁实践的改变
- 作者认为,在严重酒精戒断高风险个体中,将乙醇作为综合照护计划的一部分可能减少非计划入院。
- 作者指出初步发现需前瞻性研究进一步评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Prescribing of ethanol may be an alternative to benzodiazepines for managing alcohol withdrawal syndrome. We present our experience of oral ethanol prescribing within an acute United Kingdom National Health Service setting.
METHODS: A retrospective review of patients presenting with alcohol withdrawal who were managed with oral ethanol or benzodiazepines was performed from data collected across two acute care settings. Ethanol prescribing inclusion: high risk of delirium tremens, or a history of harmful alcohol consumption (typically ≥30 units/day; in which 1 unit = 8 grams of alcohol; one standard United States drink = 14 grams of alcohol) or known to have a history of severe alcohol withdrawal, alcohol-related seizures or delirium tremens. Inverse propensity score weighting was used to partially account for variance between the two patient populations.
RESULTS: Fifty (82 per cent male; average age 50.9 years) and 93 (84 per cent male; average age 46.5 years) patients in receipt of benzodiazepines or ethanol, respectively, were included. The likelihood of hospital admission was significantly reduced when individuals were managed with ethanol (odds ratio 0.206 (95 per cent confidence interval; 0.066-0.641), Wald chi-square P = 0.006). In those not admitted, the treatment type had no significant impact on length of stay or the number of occasions a pharmacological agent was required. In those admitted, treatment had no significant effect on length of stay.
DISCUSSION: We offer preliminary evidence to support a role of oral ethanol in the management of patients with alcohol withdrawal. We have implemented a robust and translatable guideline. Despite limitations in the data set the impact of ethanol in reducing the likelihood of admission remained significant.
CONCLUSIONS: In individuals at significant risk of severe alcohol withdrawal, prescribing ethanol as part of a comprehensive care plan, may reduce unplanned admissions. The preliminary findings presented here warrant further assessment through prospective studies.
参考来源
- Quelch D, Copland A, Kaur J, et al. Oral ethanol prescribing for alcohol withdrawal syndrome: initial findings and future directions following implementation within a United Kingdom National Health Service setting. Clin Toxicol (Phila). 2024. PMID: 38913748. doi:10.1080/15563650.2024.2363381
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。